

Supplementary Figure S1. Individual and mean (\pm standard deviation) tusamitamab ravtansine maximum plasma concentrations by dose level after first administration in Cohort Q2W-LD (A) and Cohort Q3W (B).

C_{max} , maximum plasma concentration; Q2W-LD, cohort receiving a loading dose at Day 1, Cycle 1, followed by a fixed dose every 2 weeks; Q3W, cohort receiving tusamitamab ravtansine every 3 weeks; SD, standard deviation.

